

Application No. 09/750,609

- |      |                  |  |
|------|------------------|--|
| II   | 18-32, 40-50, 68 | Oligonucleotides, a kit and an isolated nucleic acid, vector and recombinant host cell, including SEQ ID Nos. 3-4, 13-14 and 32-34.                            |
| III  | 33-36, 51, 59-64 | An isolated and purified biologically active human NE transporter polypeptide, including SEQ ID Nos. 2-4, 12-14.   |
| IV   | 37-38, 54-57     | An isolated and purified antibody and method of producing the same, including SEQ ID Nos. 2-4, 12-14.  |
| V    | 39               | A hybridoma cell line, including SEQ ID Nos. 2-4, 12-14.   |
| VI   | 52-53, 71-79     | A method of detecting RNA and DNA and a method to enhance transport of NE and detection of impaired NE transport, including SEQ ID Nos. 1-2, 11-14, and 32-34. |
| VII  | 58               | A method of detecting polypeptide, including SEQ ID Nos. 3-4, 13-14 and 32-34.   |
| VIII | 65-66            | A method of detecting antibody, including SEQ ID Nos. 3-4, 13-14 and 32-34.  |
| IX   | 69-70            | A transgenic non-human animal, including SEQ ID Nos. 3-4, 13-14 and 32-34.   |

#### APPLICANTS' ELECTION

Applicants hereby elect the invention of Group I, claims 1 through 17, drawn to a method of screening for susceptibility to sub-optimal norepinephrine (NE) transport in a subject, including using SEQ ID Nos. 9-10 for prosecution at this time.

#### REMARKS

Claims 1-79 are now pending in the subject U.S. patent application. Claims 1-79 as filed have been subjected to a Restriction/Election Requirement.

In response to the Restriction/Election Requirement, applicants have elected the claims of Group I, claims 1 – 17, for prosecution at this time.